Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion

Journal of General Virology

Volumn 86, Issue 1, 2005, Pages 131-138

  Cheung, Linda ^a   McLain, Lesley ^a   Hollier, Mark J ^a,b   Reading, Steven A ^a   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G; MATRIX PROTEIN; PROTEIN P17; SAPONIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FUSION; CELL MEMBRANE; CELL PERMEABILIZATION; CELL SURFACE; CONTROLLED STUDY; DATA ANALYSIS; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOBLASTOID CELL; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRION; VIRUS ENVELOPE;

CELL FUSION; CELL LINE; CELL LINE, TRANSFORMED; CELL WALL; HELA CELLS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; T-LYMPHOCYTES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA; VACCINIA VIRUS;

EID: 11444251893     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80439-0     Document Type: Article

References (66)

1. Abacioglu, Y. H., Fouts, T. R., Laman, J. D., Classen, E., Pincus, S. H., Moore, J. P., Roby, C. A., Kamin-Lewis, R. & Lewis, G. K. (1994). Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retrovir 10, 371-381.
2. Armstrong, S. J., McInerney, T. L., McLain, L., Wahren, B., Hinkula, J., Levi, M. & Dimmock, N. J. (1996). Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. J Gen Virol 77, 2931-2941.
3. Berlioz-Torrent, C., Shacklett, B. L., Erdtmann, L., Delamarre, L., Bouchaert, I., Sonigo, P., Dokhelar, M. C. & Benarous, R. (1999). Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adapter complexes modulate intracellular and cell surface expression of envelope glycoprotein. J Virol 73, 1350-1361.
4. Bukrinskaya, A. G. & Sharova, N. K. (1990). Unusual features of protein interaction in human immunodeficiency virus (HIV) virions. Arch Virol 110, 287-293.
5. Buratti, E., McLain, L., Tisminetzky, S. G., Cleveland, S. M., Dimmock N. J. & Baralle, F. E. (1998). The neutralizing antibody response against a conserved region of HIV-1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol 79, 2709-2716.
6. Burton, D. R., Pyati, J., Koduri, R. & 15 other authors (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027.
7. Caffrey, M., Cai, M., Kaufman, J., Stahl, S. J., Wingfield, P. T., Covell, D. G., Gronenborn, A. M. & Clore, G. M. (1998) Three-dimensional solution of the 44 kDa ectodomain of SIV gp41. EMBO J 17, 4572-4584.
8. Celma, C. C. P., Manrique, J. M., Affranchino, J. L., Hunter, E. & González, S. A. (2001). Domains in the simian immunodeficiency virus gp41 cytoplasmic tail required for envelope incorporation into particles. Virology 283, 253-261.
9. Chan, D. C., Fass, D., Berger, J. & Kim, P. S. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273.
10. Chanh, T. C., Dreesman, G., Kanda, P., Linette, G. P., Sparrow, J. T., Ho, D. D. & Kennedy, R. C. (1986). Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 5 3065-3071.
11. Cheung, L. H. Y. (2002). Antibody specificities stimulated by cowpea mosaic virus-HIV chimeras. PhD thesis, University of Warwick, Coventry, UK.
12. Cleveland, S. M. (1999). HIV-1 specific antibody responses to a plant virus-HIV chimera. PhD thesis, University of Warwick, Coventry, UK.
13. Cleveland, S. M., Buratti, E., Jones, T. D., North, P., Baralle, F. E., McLain, L., McInerney, T. L., Durrani, Z. & Dimmock, N. J. (2000a). Immunogenic and antigenic dominance of a non-neutralizing epitope over a highly conserved neutralizing epitope in the gp41 transmembrane envelope glycoprotein of HIV-1: its deletion leads to a strong neutralizing antibody response. Virology 266, 66-78.
14. Cleveland, S. M., Jones, T. D. & Dimmock, N. J. (2000b) Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the C-terminal tail of human immunodeficiency virus type 1. J Gen Virol 81, 1251-1260.
15. Cleveland, S. M., McLain, L., Cheung, L., Jones, T., Hollier, M. & Dimmock N. J. (2003). A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J Gen Virol 84, 591-602.
16. Cosson, P. (1996). Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J 15, 5783-5788.
17. Dalgleish, A. G., Chanh, T. C., Kennedy, R. C., Kanda, P., Clapham, P. R. & Weiss, R. A. (1988). Neutralization of diverse strains of HIV-1 by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165, 209-215.
18. Di Fiore, P. P. & Gill, G. N. (1999). Endocytosis and mitogenic signalling. Curr Opin Cell Biol 11, 483-488.
19. Dorfman, T., Mammano, F., Haseltine, W. A. & Göttlinger, H. G. (1994). Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope protein. J Virol 68, 1689-1696.
20. Durrani, Z., McInerney, T. L., McLain, L., Jones, T., Bellaby, T., Brennan, F. R. & Dimmock, N. J. (1998). Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods 220, 93-103.
21. Edwards, T. G., Hoffman, T. L., Baribaud, F. & 7 other authors (2001). Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 75, 5230-5239.
22. Edwards, T. G., Wyss, S., Reeves, J. D., Zolla-Pazner, S., Hoxie, J. A., Doms, R. W. & Baribaud, F. (2002). Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 76, 2683-2691.
23. Evans, D. J., McKeating, J. A., Meredith, J. M., Burke, K. L., Katrak, K., Ferguson, M., Minor, P. D., Weiss, R. A. & Almond, J. W. (1989). An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339, 385-388.
24. Ferns, R. B., Tedder, R. S. & Weiss, R. A. (1987). Characterization of monoclonal antibodies against the human immunodeficiency virus (HIV) gag products and their use in monitoring HIV isolate variation. J Gen Virol 68, 1543-1551.
25. Freed, E. O. & Martin, M. A. (1995a). The role of the human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 270, 23883-23886.
26. Freed, E. O. & Martin, M. A. (1995b). Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 69 1984-1989.
27. Freed, E. O. & Martin, M. A. (1996). Domains on the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 70, 341-351.
28. Fultz, P. N., Vance, P. J., Endres, M. J. & 8 other authors (2001). In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol 75, 278-291.
29. Gallaher, W. R., Ball, J. M., Garry, R. F., Griffin, M. C. & Montelaro, R. C. (1989). A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retrovir 5 431-440.
30. Heilker, R., Spiess, M. & Crottet P. (1999). Recognition of sorting signals by clathrin adapters. Bioessays 7 558-567.
31. Ho, D. D., Sarngadharan, M. G., Hirsch, M. S., Schooley, R. T., Rota, T. R., Kennedy, R. C., Chanh, T. C. & Sato, V. L. (1987 . Human immunodeficiency virus neutralizing antibodies recognise several conserved domains on the envelope glycoprotein. J Virol 61, 2024-2028.
32. Iwatani, Y., Ueno, T., Nishimura, A., Zhang, X., Hattori, T., Ishimoto, A., Ito, M. & Sakai, H. (2001). Modification of virus infectivity by cytoplasmic tail of HIV-1 TM protein. Virus Res 74, 75-87.
33. Jackson, N. A. C., Levi, M., Wahren, B. & Dimmock, N. J. (1999). Mechanism of action of a 17 amino acid microantibody specific for the V3 loop that neutralizes free HIV-1 virions. J Gen Virol 80, 225-236.
34. Kennedy, R. C., Henkel, R. D., Pauletti, D., Allan, J. S., Lee, T. H., Essex, M. & Dreesman, G. R. (1986). Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science 231, 1556-1559.
35. Levy, J. A. (1998). HIV and the Pathogenesis of AIDS 2nd edn. Herndon, VA: ASM Press.
36. Malashkevitch, V. N., Chan, D. C., Chutowski, C. T. & Kim, P. S. (1998). Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A 95, 9134-9139.
37. Mammano, F., Kondo, E., Sodroski, J., Bukovsky, A. & Göttlinger, H. G. (1995). Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic tails. J Virol 69, 3824-3830.
38. Manrique, J. M., Celma, C. C. P., Affranchino, J. L., Hunter, E. & González, S. A. (2001). Small variations in the length of the cytoplasmic domain of the simian immunodeficiency virus transmembrane protein drastically affect envelope incorporation and virus entry. AIDS Res Hum Retrovir 17, 1615-1624.
39. McInerney, T. L., McLain, L., Armstrong, S. J. & Dimmock, N. J. (1997). A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a post-fusion event. Virology 233 313-326.
40. McLain, L. & Dimmock, N. J. (1994). Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol 75, 1457-1460.
41. McLain, L., Porta, C., Lomonossoff, G. P., Durrani, Z. & Dimmock, N. J. (1995). Human immunodeficiency virus type 1 neutralizing antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res Hum Retrovir 11, 327-334.
42. McLain, L., Durrani, Z., Wisniewski, L. A., Porta, C., Lomonossoff, G. P. & Dimmock, N. J. (1996a). A plant virus-HIV-1 chimera stimulates antibody that neutralizes HIV-1. In Vaccines 96, pp. 311-316. Edited by F. Brown, D. R. Burton, J. Collier, J. Mekalonos & E. Norrby. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
43. McLain, L., Durrani, Z., Wisniewski, L. A., Porta, C., Lomonossoff, G. P. & Dimmock, N. J. (1996b). Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22-mer amino acid peptide expressed on the surface of a plant virus. Vaccine 14, 799-810.
44. McLain, L., Brown, J. L., Cheung, L., Reading, S. A., Parry, C., Jones, T. D., Cleveland, S. M. & Dimmock, N. J. (2001 . Different effects of a single amino acid substitution on three epitopes in the gp41 C-terminal loop of a neutralizing antibody escape mutant of human immunodeficiency virus type 1. Arch Virol 146, 157-166.
45. Mulligan, M. J., Yamshchikov, G. V., Ritter, G. D., Gao, F., Jin, M. J., Nail, C. D., Spies, C. P., Hahn, B. H. & Compans, R. W. (1992). Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in certain cell types. J Virol 66, 3971-3975.
46. Murakami, T. & Freed, E. O. (2000a). Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix protein and α-helix 2 of the gp41 cytoplasmic tail. J Virol 74 3548-3554.
47. Murakami, T. & Freed, E. O. (2000b). The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A 97, 343-348.
48. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F. & Katinger, H. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67, 6642-6647.
49. Newton, S. M. C., Joys, T. M., Anderson, S. A., Kennedy, R. C. Hovi, M. E. & Stocker, B. A. D. (1995). Expression and immunogenicity of an 18-residue epitope of HIV-1 gp41 inserted in the flagellar protein of a Salmonella live vaccine. Res Microbiol 146, 203-216.
50. Nixon, D. F., Townsend, A. R. M., Elvin, J. G., Rizza, C. R., Gallwey, J. & McMichael, A. J. (1988). HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336, 484-489.
51. Piller, S. C., Dubay, J. W., Derdeyn, C. A. & Hunter, E. (2000). Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol 74, 11717-11723.
52. Porta, C. & Lomonossoff, G. P. (1998). Scope for plant viruses to present epitopes from animal pathogens. Rev Med Virol 8, 25-41.
53. Ratner, L., Haseltine, W., Patarca, R. & 16 other authors (1985). Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284.
54. Reading, S. A., Heap, C. J. & Dimmock, N. J. (2003). A novel monoclonal antibody specific for the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny. Virology 315, 362-372.
55. Sattentau, Q. J., Zolla-Pazner, S. & Poignard, P. (1995) Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206, 713-717.
56. Sauter, M. M., Pelchen-Matthews, A., Bron, R. & 8 other authors (1996). An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol 132, 795-811.
57. Sodroski, J., Goh, W. C., Rosen, C., Campbell, K. & Haseltine, W. A. (1986). Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 322, 470-474.
58. Spies, C. P., Ritter, G. D., Mulligan, M. J. & Compans, R. W. (1994). Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain. J Virol 68, 585-591.
59. Tan, K., Liu, J.-H., Wang, J.-H., Shen, S. & Liu, M. (1997). Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94, 12303-12308.
60. Vella, C., Ferguson, M., Dunn, G., Meloen, R., Langedijk, H., Evans, D. & Minor, P. D. (1993). Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J Gen Virol 74, 2603-2607.
61. Vzorov, A. N. & Compans, R. W. (2000). Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization. J Virol 74, 8219-8225.
62. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. (1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430.
63. Wilk, T., Pfeiffer, T. & Bosch, V. (1992). Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 189, 167-177.
64. Gag in immature human immunodeficiency virus type 1 particles. J Virol 74, 9381-9387.
65. Yu, X., Yuan, X., McLane, M. F., Lee, T.-H. & Essex, M. (1993). Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol 67, 213-221.
66. Zingler, K. & Littman, D. R. (1993). Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity. J Virol 67, 2824-2831.